Online citations, reference lists, and bibliographies.
← Back to Search

Lung Cancer And Other Thoracic Malignancies

M. Harkenrider, S. R. Silva, R. Decker
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Lung cancer is the deadliest malignancy in the United States, and much research has been dedicated over the last many decades to improve patient outcomes. Smoking cessation education, lung cancer screening, improved diagnostic and functional imaging, improved surgical and radiation techniques, multimodality therapy, and targeted biologic and immunologic therapy have all lead to earlier detection of lung cancer and improved treatment resulting in improvements in overall survival. There are still many controversies that exist within each of these many aspects in the diagnosis and treatment of lung cancer. This chapter is dedicated to the controversies that exist in the management and treatment of all aspects of lung cancer with additional discussion of the controversies regarding thymoma and malignant pleural mesothelioma.
This paper references
10.1002/1097-0142(197812)42:6<2600::AID-CNCR2820420614>3.0.CO;2-2
Radiation therapy in the treatment of superior vena caval obstruction
D. Davenport (1978)
10.1016/j.ejca.2011.05.012
Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma.
P. Jenkins (2011)
10.1016/j.ijrobp.2014.08.343
Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis.
W. W. Chance (2015)
10.1200/JCO.2007.15.3312
Palliative thoracic radiotherapy for lung cancer: a systematic review.
A. Fairchild (2008)
10.1056/NEJM199908123410703
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.
A. Aupérin (1999)
10.1016/j.critrevonc.2016.01.012
Thymoma and thymic carcinomas.
M. Scorsetti (2016)
10.1016/J.LUNGCAN.2007.02.004
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
F. Rea (2007)
10.1016/j.ijrobp.2009.02.072
Variations in target volume definition for postoperative radiotherapy in stage III non-small-cell lung cancer: analysis of an international contouring study.
F. Spoelstra (2010)
10.1016/J.IJROBP.2015.07.1649
Novel Predictors of Esophageal Toxicity With Stereotactic Body Radiation Therapy (SBRT) for Central Lung Tumors
K. Stang (2015)
10.1016/j.ijrobp.2015.07.2260
A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927).
G. Videtic (2015)
10.1016/J.IJROBP.2015.07.242
Prospective Phase 2 Clinical Trial of Radiation Dose-Escalated Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Lung Cancer: An Institutional Trial
J. Bradley (2015)
10.1016/j.lungcan.2010.06.019
Palliative thoracic radiotherapy in non-small cell lung cancer. An analysis of 1250 patients. Palliation of symptoms, tolerance and toxicity.
M. Reinfuss (2011)
10.1200/JCO.2008.21.5681
Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy.
P. Baumann (2009)
10.1016/J.IJROBP.2005.06.029
Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: is low incidence of regional failure due to incidental nodal irradiation?
M. Chen (2006)
10.1016/J.ATHORACSUR.2005.02.091
Pulmonary resection after high-dose and low-dose chest irradiation.
R. Cerfolio (2005)
10.1097/01.md.0000198474.99876.f0
The Superior Vena Cava Syndrome: Clinical Characteristics and Evolving Etiology
T. Rice (2006)
10.1002/14651858.CD001316.PUB2
Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus.
N. P. Rowell (2001)
10.1016/j.lungcan.2013.12.006
High-dose, conventionally fractionated thoracic reirradiation for lung tumors.
G. Griffioen (2014)
10.1002/cncr.10665
New WHO histologic classification predicts prognosis of thymic epithelial tumors
G. Chen (2002)
10.1200/JCO.2006.07.5937
Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.
R. Timmerman (2006)
10.1016/j.cllc.2011.04.004
Consensus statement on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control.
G. Rodrigues (2012)
10.1093/jnci/djr325
Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.
W. Curran (2011)
10.1016/S0022-5223(96)70265-9
Prognostic factors and long-term results after thymoma resection: a series of 307 patients.
J. Régnard (1996)
10.1016/0003-4975(95)00537-U
Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.
R. Ginsberg (1995)
10.1016/j.ijrobp.2008.06.1935
The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer.
L. Wang (2009)
10.1016/j.ijrobp.2014.05.055
Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis.
X. Zheng (2014)
10.1016/J.IJROBP.2004.06.260
Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
J. Bradley (2005)
10.1016/J.IJROBP.2015.10.039
NRG Oncology/RTOG 0937: Randomized Phase 2 Study Comparing Prophylactic Cranial Irradiation (PCI) Alone to PCI and Consolidative Extracranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)
E. Gore (2016)
10.1016/j.ijrobp.2009.02.027
Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy.
N. Dunlap (2010)
10.1056/NEJM199212033272302
A meta-analysis of thoracic radiotherapy for small-cell lung cancer.
J. Pignon (1992)
10.1016/S0936-6555(05)80540-0
Prevention of tumour seeding following thoracoscopy in mesothelioma by prophylactic radiotherapy.
E. Low (1995)
10.1093/JNCI/88.17.1210
Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
R. Dillman (1996)
10.1016/S0169-5002(03)00152-1
The role of radiotherapy in treatment of stage I non-small cell lung cancer.
X. Qiao (2003)
10.21037/jtd.2016.03.28
The role of postoperative radiotherapy for stage I/II/III thymic tumor-results of the ChART retrospective database.
Q. Liu (2016)
10.1016/S0360-3016(01)01703-5
Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience.
M. Uematsu (2001)
10.1371/journal.pone.0145039
Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients
E. Taioli (2015)
10.1016/S0360-3016(02)02989-9
Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15).
A. Bezjak (2002)
10.1016/S0169-5002(98)00008-7
Radiotherapy for locoregional recurrent tumors after resection of non-small cell lung cancer.
Y. Kagami (1998)
10.1200/JCO.1994.12.7.1484
Prognostic factors and outcome of incompletely resected invasive thymoma following radiation therapy.
I. Ciernik (1994)
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.1016/j.ijrobp.2015.01.032
Relationship Between Radiation Therapy Dose and Outcome in Patients Treated With Neoadjuvant Chemoradiation Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer: A Population-Based, Comparative Effectiveness Analysis.
D. Sher (2015)
10.1016/S0360-3016(97)00589-0
Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience.
G. Sibley (1998)
10.1136/bmjopen-2015-010589
Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention
N. Bayman (2016)
10.1053/j.semtcvs.2013.07.002
The state of the art in the technical performance of lung-sparing operations for malignant pleural mesothelioma.
J. Friedberg (2013)
Postoperative radiotherapy for stage I thymoma: a prospective randomized trial in 29 cases.
H. Zhang (1999)
10.1200/JCO.2006.08.2826
Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160).
V. Rusch (2007)
10.1016/j.athoracsur.2014.11.009
Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer.
M. Hamaji (2015)
10.1200/JCO.2005.12.120
Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
J. Bradley (2005)
10.1002/1097-0142(19940715)74:2<606::AID-CNCR2820740212>3.0.CO;2-T
Thymoma: Histologic subclassification is an independent prognostic factor
L. Quintanilla-Martinez (1994)
10.5114/jcb.2015.54038
Brachytherapy in the treatment of lung cancer – a valuable solution
J. Skowronek (2015)
10.1016/j.ijrobp.2008.10.054
Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing.
M. Feng (2009)
10.1016/J.JTCVS.2003.07.027
Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
M. Machtay (2004)
10.1097/JTO.0b013e3181adf509
A Comparison of Two Stereotactic Body Radiation Fractionation Schedules for Medically Inoperable Stage I Non-small Cell Lung Cancer: The Cleveland Clinic Experience
K. Stephans (2009)
10.1016/J.ARBRES.2014.06.005
Diagnosis and treatment of malignant pleural mesothelioma.
F. Rodríguez-Panadero (2015)
10.1200/JCO.1993.11.7.1230
Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
G. Giaccone (1993)
Role of salvage stereotactic body radiation therapy in post-surgical loco-regional recurrence in a selected population of non-small cell lung cancer patients.
L. Agolli (2015)
10.1016/S0140-6736(15)60294-X
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
M. Pless (2015)
10.1136/bmjopen-2015-009849
Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and goo
C. Faivre-Finn (2016)
10.1200/JCO.2009.26.2543
Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.
A. Aupérin (2010)
10.1016/S0360-3016(00)00509-5
A study of postoperative radiotherapy in patients with non-small-cell lung cancer: a randomized trial.
Q. Feng (2000)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.1200/JCO.2014.32.15_SUPPL.7503
Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial.
T. Seto (2014)
10.3779/J.ISSN.1009-3419.2010.01.10
Analysis of the Effect of Radiotherapy on Malignant Pleural Mesothelioma when Given on Adjuvant or Palliative Basis
H. E. Hossieny (2010)
10.1200/JCO.2005.01.685
Results of the Dutch National study of the palliative effect of irradiation using two different treatment schemes for non-small-cell lung cancer.
G. Kramer (2005)
10.1097/JTO.0b013e31821ea553
Standard Terms, Definitions, and Policies for Minimally Invasive Resection of Thymoma
A. Toker (2011)
10.1016/j.jacr.2013.05.031
ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent.
K. Rosenzweig (2013)
10.1016/j.ijrobp.2014.05.011
Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.
K. Stephans (2014)
10.1097/JTO.0b013e3181804791
Superior Vena Cava Syndrome—A Proposed Classification System and Algorithm for Management
J. Yu (2008)
10.1097/JTO.0b013e3182208e3f
Recommendations for Uniform Definitions of Surgical Techniques for Malignant Pleural Mesothelioma: A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group
D. Rice (2011)
10.1016/0360-3016(80)90105-4
Postoperative radiation therapy in lung caner: a controlled trial after resection of curative design.
P. van Houtte (1980)
10.1097/JTO.0b013e3181f20ea2
Technical advances of radiation therapy for thymic malignancies.
D. Gomez (2010)
10.1002/ijc.11099
Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignancies
E. Engels (2003)
10.1016/S0003-4975(03)00555-1
Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan.
K. Kondo (2003)
10.1016/j.cllc.2011.11.002
International practice survey on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control.
G. Rodrigues (2012)
10.1378/CHEST.117.2.358
Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
W. Sause (2000)
10.1097/JTO.0b013e31821ea60c
Radiation Therapy Definitions and Reporting Guidelines for Thymic Malignancies
D. Gomez (2011)
10.1016/j.ijrobp.2012.03.041
Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung.
Ryan A. Baker (2013)
10.1097/JTO.0b013e3181f1903e
Frequency of Use and Predictors of Cancer-Directed Surgery in the Management of Malignant Pleural Mesothelioma in a Community-Based (Surveillance, Epidemiology, and End Results [SEER]) Population
R. Flores (2010)
10.1016/j.lungcan.2009.05.007
Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial.
U. Ricardi (2010)
10.1016/S0169-5002(01)00381-6
Radiation therapy of stage I and II non-small cell lung cancer (NSCLC).
D. Zierhut (2001)
10.1016/j.athoracsur.2012.04.088
The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy.
A. Amini (2012)
10.1097/JTO.0b013e31822e71d8
Outcomes of Stereotactic Ablative Radiotherapy for Centrally Located Early-Stage Lung Cancer
C. Haasbeek (2011)
10.1016/j.athoracsur.2014.04.040
Women with malignant pleural mesothelioma have a threefold better survival rate than men.
E. Taioli (2014)
10.1097/JTO.0b013e318074de34
Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional Study
H. Onishi (2007)
10.1097/JTO.0b013e31823c485f
Results of Proton Beam Therapy without Concurrent Chemotherapy for Patients with Unresectable Stage III Non-small Cell Lung Cancer
Y. Oshiro (2012)
10.1016/j.lungcan.2013.11.004
Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review.
N. Macleod (2014)
10.1258/ar.2011.100377
High resolution spiral CT for determining the malignant potential of solitary pulmonary nodules: refining and testing the test
S. Harders (2011)
10.1016/J.IJROBP.2014.05.135
Long-term Results of RTOG 0236: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Medically Inoperable Stage I Non-Small Cell Lung Cancer
R. Timmerman (2014)
10.1200/JCO.2006.09.6263
Need for a new trial to evaluate adjuvant postoperative radiotherapy in non-small-cell lung cancer patients with N2 mediastinal involvement.
C. le Péchoux (2007)
10.1056/NEJMOA071780
Prophylactic cranial irradiation in extensive small-cell lung cancer.
B. Slotman (2007)
10.1097/JTO.0b013e3181f1f62d
Epidemiology of Thymoma and Associated Malignancies
E. Engels (2010)
10.1111/j.1440-1827.1994.tb02936.x
A review of 79 thymomas: Modification of staging system and reappraisal of conventional division into invasive and non‐invasive thymoma
K. Koga (1994)
10.1056/NEJM199901283400403
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.
A. Turrisi (1999)
10.1016/j.ijrobp.2011.11.057
Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy.
P. Patel (2012)
10.1016/j.lungcan.2015.02.008
High-dose conventional thoracic re-irradiation for lung cancer: updated results.
S. Tetar (2015)
10.1016/J.IJROBP.2005.05.034
Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame.
Y. Nagata (2005)
10.1200/JCO.2009.27.1205
Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117.
J. Bradley (2010)
10.1016/j.radonc.2009.04.018
Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites.
Jeffrey A. Forquer (2009)
10.1016/S1470-2045(15)70168-3
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.
J. Chang (2015)
10.1016/j.lungcan.2011.05.003
Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer.
D. Shumway (2011)
10.1186/1748-717X-9-210
Stereotactic Body Radiation Therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review
A. Amini (2014)
10.1002/cncr.26277
A prospective phase 2 study of surgery followed by chemotherapy and radiation for superior sulcus tumors
D. Gomez (2012)
10.1016/j.ijrobp.2014.12.026
Risk of hippocampal metastases in small cell lung cancer patients at presentation and after cranial irradiation: a safety profile study for hippocampal sparing during prophylactic or therapeutic cranial irradiation.
V. Kundapur (2015)
10.1016/j.ijrobp.2015.06.029
Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors.
E. Minatel (2015)
10.1016/j.radonc.2011.06.031
Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC).
M. Baumann (2011)
10.1097/00000441-195401000-00007
THE SUPERIOR VENA CAVA SYNDROME
M. Schechter (1954)
10.3978/j.issn.2218-6751.2015.04.07
Which patients with extensive stage small-cell lung cancer should and should not receive thoracic radiotherapy?
B. Slotman (2015)
10.1016/j.ijrobp.2008.08.001
Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer.
J. Chang (2008)
10.3389/fonc.2013.00330
Radiotherapy for Thymic Carcinoma: Adjuvant, Inductive, and Definitive
R. Komaki (2014)
10.1016/0360-3016(92)91013-D
Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies.
D. Dosoretz (1992)
10.1186/s13014-015-0575-5
Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy
C. Thieke (2015)
10.1002/(SICI)1096-9098(199609)63:1<17::AID-JSO4>3.0.CO;2-T
Preoperative radiotherapy and surgery for advanced thymoma with invasion to the great vessels
E. Akaogi (1996)
10.1200/JCO.1995.13.8.1880
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
K. Albain (1995)
10.1378/chest.12-2351
Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
M. Gould (2013)
10.1111/J.1440-1673.1994.TB00177.X
Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation.
S. Davis (1994)
10.1200/JCO.2015.61.1517
Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer.
E. Wang (2015)
10.1016/J.ATHORACSUR.2004.04.085
Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
J. Sonett (2004)
10.1016/S0360-3016(99)00133-9
Intraoperative 125I brachytherapy for high-risk stage I non-small cell lung carcinoma.
A. Chen (1999)
10.1016/j.radonc.2015.05.014
Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer.
Q. Nguyen (2015)
10.1200/JCO.1999.17.7.2092
Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study.
B. Jeremic (1999)
10.1002/cncr.28267
Effect of prophylactic cranial irradiation on survival in elderly patients with limited‐stage small cell lung cancer
B. Eaton (2013)
10.1093/JNCI/87.3.198
Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.
W. Sause (1995)
10.1016/j.jtcvs.2015.09.129
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2016)
10.1016/S0360-3016(01)02656-6
Postoperative radiotherapy in thymic carcinoma: treatment results and prognostic factors.
H. C. Hsu (2002)
Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.
C. Blomberg (2015)
10.1016/S0360-3016(96)00364-1
Prognostic factors in the treatment of node-negative nonsmall cell lung carcinoma with radiotherapy alone.
P. Kupelian (1996)
10.1016/j.lungcan.2015.03.007
Does myasthenia gravis influence overall survival and cumulative incidence of recurrence in thymoma patients? A Retrospective clinicopathological multicentre analysis on 797 patients.
P. Filosso (2015)
10.1378/chest.08-2665
Malignant pleural mesothelioma: an update on biomarkers and treatment.
M. Ray (2009)
10.1016/j.ijrobp.2009.06.037
Radiotherapy in malignant pleural mesothelioma.
M. McAleer (2009)
10.1016/j.ijrobp.2009.04.075
Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study.
J. van Loon (2010)
10.1097/COC.0b013e318277d822
Stereotactic Body Radiation Therapy for Unbiopsied Early-stage Lung Cancer: A Multi-Institutional Analysis
M. Harkenrider (2014)
10.1016/S0003-4975(97)00629-2
Multimodality treatment of thymoma: a prospective study.
F. Venuta (1997)
10.1016/S1470-2045(09)70101-9
Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial.
C. le Péchoux (2009)
10.1016/j.cllc.2014.10.005
Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation.
C. Swanick (2015)
10.1186/1748-717X-7-33
Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer
A. Amini (2012)
10.1097/JTO.0b013e31816fca1b
Trimodality Treatment of Malignant Pleural Mesothelioma
H. Batırel (2008)
10.1016/j.ijrobp.2009.10.030
Mature follow-up for high-risk stage I non-small-cell lung carcinoma treated with sublobar resection and intraoperative iodine-125 brachytherapy.
A. Colonias (2011)
10.1016/S0169-5002(99)00007-0
External beam radiation therapy alone for loco-regional recurrence of non-small-cell lung cancer after complete resection.
B. Jeremic (1999)
10.1097/JTO.0b013e3181ae25bf
Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia
A. Hasani (2009)
10.1080/10408440903044928
Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through 2005
B. Price (2009)
10.1016/j.radonc.2016.02.003
Prospective study of proton beam radiation therapy for adjuvant and definitive treatment of thymoma and thymic carcinoma: Early response and toxicity assessment.
J. Vogel (2016)
10.1111/cas.12955
Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non‐small cell lung cancer
H. Harada (2016)
10.1016/j.ijrobp.2014.10.002
Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
M. Koshy (2015)
10.1016/j.ijrobp.2010.04.056
Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial.
S. Bral (2011)
10.1016/j.ijrobp.2008.01.044
Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.
J. Douillard (2008)
10.1200/JCO.2006.10.3747
A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer.
F. Kong (2007)
10.1016/j.ejcts.2008.12.029
Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival.
R. Cerfolio (2009)
10.1038/bjc.1997.123
A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small-cell lung cancer.
D. Ball (1997)
10.1016/J.ARBRES.2014.06.005
Diagnóstico y tratamiento del mesotelioma pleural maligno
Francisco Rodríguez Panadero (2015)
10.1097/00130404-200311000-00008
Promising Early Local Control of Malignant Pleural Mesothelioma Following Postoperative Intensity Modulated Radiotherapy (IMRT) to the Chest
A. Ahamad (2003)
10.1097/JTO.0b013e318279155f
Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States
M. Daly (2013)
10.1016/S1470-2045(14)71207-0
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
J. Bradley (2015)
10.1016/0924-4212(96)81747-6
Palliative effectiveness of radiation therapy in the treatment of superior vena cava syndrome.
A. Egelmeers (1996)
10.1016/j.ijrobp.2012.01.018
Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer.
Y. Matsuo (2012)
10.1016/j.prro.2011.01.005
Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline
G. Rodrigues (2011)
10.1023/A:1011131303391
A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
D. Mavroudis (2001)
10.1016/S0167-8140(99)00087-0
Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee.
M. Saunders (1999)
10.1016/S0039-6060(03)00327-1
Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with Stage I non-small-cell lung cancer.
R. Santos (2003)
10.1016/S0140-6736(98)06341-7
Postoperative radiotherapy in nonsmall-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials
S. Burdett (1998)
10.1002/cncr.26119
Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited‐stage small cell lung cancer
X. Hu (2012)
5-year prospective results of trimodality treatment for malignant pleural mesothelioma.
V. Pagan (2006)
10.1016/J.IJROBP.2006.01.051
Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis.
F. Kong (2006)
10.1200/JCO.1994.12.10.2022
Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
D. Ihde (1994)
10.1097/JTO.0000000000000472
Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011)
E. Kim (2015)
10.1093/ejcts/ezs663
Thymoma and the increased risk of developing extrathymic malignancies: a multicentre study.
P. Filosso (2013)
10.1016/j.lungcan.2011.04.014
Chemotherapy and targeted therapies for unresectable malignant mesothelioma.
R. Kelly (2011)
10.2146/ajhp110281
Malignant pleural mesothelioma.
Sheree E Chen (2012)
10.1111/cas.12466
Meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer
Jie-tao Ma (2014)
10.1378/chest.13-2924
When is a biopsy-proven diagnosis necessary before stereotactic ablative radiotherapy for lung cancer?: A decision analysis.
A. Louie (2014)
10.1002/cncr.20539
Stereotactic hypofractionated high‐dose irradiation for stage I nonsmall cell lung carcinoma
H. Onishi (2004)
10.1016/j.radonc.2011.09.017
Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease.
N. Verstegen (2011)
10.1016/S1470-2045(14)70345-6
High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer.
D. de Ruysscher (2014)
10.1016/j.ijrobp.2015.07.2278
Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403.
Y. Nagata (2015)
10.1016/S0360-3016(98)00409-X
Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura--a single-institution experience with 189 patients.
L. de Graaf-Strukowska (1999)
10.1016/j.critrevonc.2010.04.004
Malignant pleural mesothelioma: the standard of care and challenges for future management.
J. Van Meerbeeck (2011)
10.1093/annonc/mdt241
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J. Vansteenkiste (2013)
10.1001/JAMA.285.7.914
Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis.
M. Gould (2001)
10.1016/S1556-0864(15)31583-5
Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial
R. Flores (2006)
10.1186/s40064-016-1900-7
Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome
C. Straka (2016)
10.1016/0360-3016(93)90374-5
Radiation therapy alone for stage I non-small cell lung cancer.
L. Kaskowitz (1993)
10.1378/CHEST.112.4.954
Postoperative radiotherapy in radically resected non-small cell lung cancer.
R. Mayer (1997)
10.1016/j.ijrobp.2012.01.075
Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239.
R. Komaki (2012)
10.1097/JTO.0b013e3182a5097b
Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and a Single-Station Involvement
J. Okami (2013)
10.1016/S0022-5223(95)70427-2
Incidence of local recurrence and second primary tumors in resected stage I lung cancer.
N. Martini (1995)
10.1002/(SICI)1097-0142(19990715)86:2<265::AID-CNCR10>3.0.CO;2-B
A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma
B. Dautzenberg (1999)
10.1016/j.cllc.2015.09.007
Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Meta-Analysis.
D. Palma (2016)
10.1097/JTO.0b013e31827740f0
Patterns of Failure, Toxicity, and Survival after Extrapleural Pneumonectomy and Hemithoracic Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma
D. Gomez (2013)
10.1097/JTO.0000000000000406
Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database
C. Corso (2015)
10.1056/NEJMoa1102873
Reduced lung-cancer mortality with low-dose computed tomographic screening.
D. Aberle (2011)
10.1016/j.ijrobp.2011.06.2003
Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
F. Lagerwaard (2012)
10.1200/JCO.2002.03.055
Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.
K. Albain (2002)
10.1200/JCO.2008.17.0746
Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups.
B. Slotman (2009)
10.1016/j.ijrobp.2009.09.066
Role of adjuvant radiotherapy for stage II thymoma after complete tumor resection.
Y. Chen (2010)
10.1016/j.athoracsur.2015.06.034
The Effectiveness of Postoperative Radiotherapy in Patients With Completely Resected Thymoma: A Meta-Analysis.
D. Zhou (2016)
10.1016/j.athoracsur.2013.06.014
Salvage stereotactic ablative irradiation for isolated postsurgical local recurrence of lung cancer.
A. Takeda (2013)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1186/s12885-015-1036-0
Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R1 resection) in non-small-cell lung cancer
M. Zhou (2015)
10.1016/S1051-0443(97)70660-2
Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy.
A. A. Nicholson (1997)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/S0140-6736(14)61085-0
Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial
B. Slotman (2015)
10.1016/J.IJROBP.2015.10.040
Primary Study Endpoint Analysis for NRG Oncology/RTOG 0813 Trial of Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Non-Small Cell Lung Cancer (NSCLC)
A. Bezjak (2016)
10.1001/ARCHINTE.1997.00440290031002
The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules.
S. Swensen (1997)
10.1097/JTO.0b013e31821e8cff
The Masaoka-Koga Stage Classification for Thymic Malignancies: Clarification and Definition of Terms
F. Detterbeck (2011)
10.1016/j.ijrobp.2011.09.027
Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.
K. Rosenzweig (2012)
10.1093/JJCO/HYS114
Comparison of treatment outcomes between involved-field and elective nodal irradiation in limited-stage small cell lung cancer.
Tae Jin Han (2012)
10.1056/NEJM199010043231403
A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.
R. Dillman (1990)
10.1177/1753465816628800
Malignant pleural mesothelioma: an update on diagnosis and treatment options
Sanjana Kondola (2016)
10.1007/s00270-012-0421-1
Life-threatening Cerebral Edema Caused by Acute Occlusion of a Superior Vena Cava Stent
K. Sofue (2012)
10.1002/JSO.2930520412
Treatment and prognosis of primary thymic carcinoma
T. Yano (1993)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
10.1007/s10147-005-0526-5
Non-small cell lung cancer: radiation therapy for locoregional recurrence after complete resection
T. Tada (2005)
10.1001/jama.2010.261
Stereotactic body radiation therapy for inoperable early stage lung cancer.
R. Timmerman (2010)
10.1016/j.lungcan.2009.08.019
Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.
S. Boeluekbas (2011)
10.1016/j.lungcan.2012.01.006
Stereotactic body radiotherapy (SBRT) for solitary pulmonary nodules clinically diagnosed as lung cancer with no pathological confirmation: comparison with non-small-cell lung cancer.
A. Takeda (2012)
10.1002/cncr.10588
Treatment and prognosis of thymic carcinoma
K. Ogawa (2002)
10.1016/S0140-6736(09)60737-6
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
K. Albain (2009)
10.1016/j.ijrobp.2012.10.016
Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey.
R. Komaki (2013)
10.1016/J.CLON.2004.09.008
Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules.
S. Erridge (2005)
10.1200/JCO.2007.14.7371
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
M. Socinski (2008)
10.1056/NEJMCP067190
Superior Vena Cava Syndrome with Malignant Causes
L. Wilson (2007)
10.1200/JCO.2013.31.15_SUPPL.7523
RTOG 0618: Stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients.
R. Timmerman (2013)
10.1001/JAMA.283.9.1142
Association between thymoma and second neoplasms.
J. Welsh (2000)
10.1007/s00520-001-0313-4
Double-flash, large-fraction radiation therapy as palliative treatment of malignant superior vena cava syndrome in the elderly
F. Lonardi (2001)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1016/j.ijrobp.2014.08.345
Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis.
V. Mangona (2015)
10.1016/J.ATHORACSUR.2005.08.052
Sublobar resection with brachytherapy versus lobectomy for stage Ib nonsmall cell lung cancer.
T. Birdas (2006)
10.1016/S0167-8140(03)00229-9
Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch-Belgian survey.
D. D. De Ruysscher (2003)
10.1016/J.ATHORACSUR.2004.12.047
Advanced stage thymomas and thymic carcinomas: results of multimodality treatments.
M. Lucchi (2005)
10.1016/J.LUNGCAN.2003.12.010
Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report.
E. Kim (2004)
10.1097/CRD.0b013e318188033c
Superior Vena Cava Syndrome: A Contemporary Review of a Historic Disease
S. Cheng (2009)
10.1016/S0360-3016(97)00365-9
Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.
R. Komaki (1997)
10.1016/j.ijrobp.2015.11.004
A Phase 2 Trial of Concurrent Chemotherapy and Proton Therapy for Stage III Non-Small Cell Lung Cancer: Results and Reflections Following Early Closure of a Single-Institution Study.
B. Hoppe (2016)
10.1200/JCO.2009.25.0928
Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer.
I. Grills (2010)
10.1016/j.ijrobp.2013.03.035
Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer.
D. Gomez (2013)
10.1016/j.athoracsur.2011.02.052
Accuracy of FDG-PET to diagnose lung cancer in a region of endemic granulomatous disease.
S. Deppen (2011)
10.1200/JCO.2016.34.15_SUPPL.8504
CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS).
C. Faivre-Finn (2016)
10.1097/00000658-199608000-00016
Is postoperative radiotherapy for thymoma effective?
M. Haniuda (1996)
10.1016/J.RADONC.2007.05.022
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
10.5306/wjco.v5.i5.1048
Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer.
T. Yano (2014)
10.1016/J.IJROBP.2003.10.021
70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.
J. Bogart (2004)
10.1200/JCO.2004.11.089
Positron emission tomography in limited-stage small-cell lung cancer: a prospective study.
J. Bradley (2004)
10.3857/roj.2014.32.3.147
The single institutional outcome of postoperative radiotherapy and concurrent chemoradiotherapy in resected non-small cell lung cancer
H. C. Lee (2014)
10.1016/j.cllc.2011.11.008
Proton therapy with concurrent chemotherapy for non-small-cell lung cancer: technique and early results.
B. Hoppe (2012)
10.1016/j.ijrobp.2008.11.042
Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study.
A. Fakiris (2009)
10.1016/0360-3016(87)90068-X
Role of irradiation in the management of superior vena cava syndrome.
B. Armstrong (1987)
10.3978/j.issn.2305-5839.2015.07.03
Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.
Weiquan Zhang (2015)
10.1016/0360-3016(80)90106-6
Patterns of tumor recurrence after definitive irradiation for inoperable non-oat cell carcinoma of the lung.
C. Perez (1980)
10.2147/OTT.S87222
Treatment and survival analyses of completely resected thymic carcinoma patients
Y. Mao (2015)
10.1016/S0936-6555(05)80582-5
The role of palliative radiotherapy in malignant mesothelioma.
D. Bissett (1991)
10.1378/CHEST.106.6_SUPPLEMENT.297S
Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. LCSG 773.
T. Weisenburger (1994)
10.1097/JTO.0b013e31828f68b4
Improved Survival Associated with Neoadjuvant Chemoradiation in Patients with Clinical Stage IIIA(N2) Non–Small-Cell Lung Cancer
M. Koshy (2013)
10.1016/j.ijrobp.2010.08.056
A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy.
R. Barriger (2012)
10.1016/j.ijrobp.2014.05.048
Salvage stereotactic body radiation therapy (SBRT) for local failure after primary lung SBRT.
J. Hearn (2014)
10.1200/JCO.1988.6.11.1722
Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection.
W. Curran (1988)
10.1016/j.lungcan.2011.12.009
Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure.
O. Rena (2012)
10.21037/tlcr.2016.04.05
Is surgery still the optimal treatment for stage I non-small cell lung cancer?
D. Moghanaki (2016)
10.1016/S0360-3016(03)00287-6
Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma.
S. Yajnik (2003)
10.1038/bjc.1996.413
The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party.
R. Stephens (1996)
10.1097/JTO.0b013e3182199819
Intensity-Modulated Radiotherapy After Extrapleural Pneumonectomy in the Combined-Modality Treatment of Malignant Pleural Mesothelioma
A. Chi (2011)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R
Follow‐up study of thymomas with special reference to their clinical stages
A. Masaoka (1981)
10.1016/j.lungcan.2011.09.015
Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial.
R. Colaco (2012)
10.1016/j.radonc.2011.09.025
Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series.
S. Tonoli (2011)
10.1378/CHEST.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.1056/NEJM198704093161504
Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung.
M. C. Perry (1987)
10.1016/J.RADONC.2006.07.029
Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial.
D. D. De Ruysscher (2006)
10.1200/JCO.2013.53.4115
Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer.
H. Fernando (2014)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar